Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Acute Treatment of Migraine Attacks: For adults and adolescents aged 12 to 17, the recommended dose of Almotriptan is 6.25 mg to 12.5 mg, and in adults the 12.5 mg dose tends to work better. If the headache eases after the first dose of almotriptan malate but comes back, a second dose may be taken after 2 hours. The total daily dose should not go beyond 25 mg. Treating more than an average of four migraines per 30 days has not been established as safe. Hepatic Impairment: In patients with hepatic impairment, the recommended starting dose of almotriptan malate is 6.25 mg, and the total dose over 24 hours should not go beyond 12.5 mg. Renal Impairment: In patients with severe renal impairment, the recommended starting dose of almotriptan malate is 6.25 mg, and the total dose over 24 hours should not go beyond 12.5 mg.
Side Effects
Serious heart-related reactions, including heart attack, have occurred in people taking Almitan malate Tablets. Such events are very rare and have mostly been seen in patients who already had risk factors for coronary artery disease (CAD).
Cautions & Contraindications
Warnings & Precautions
Hypersensitivity to the active substance or to any of the excipients. Patients with severe hepatic impairment, with a previous cerebrovascular accident (CVA) or transient ischaemic attack (TIA) Peripheral vascular disease.
Contraindications
Almotriptan should not be used in patients with a history, symptoms or signs of ischaemic heart disease (myocardial infarction, angina pectoris, documented silent ischaemia, Prinzmetal's angina) or severe hypertension and uncontrolled mild or moderate hypertension, as is the case with other 5-HT1B/1D receptor agonists. It should also not be given together with ergotamine, ergotamine derivatives (including methysergide) or other 5-HT1B/1D agonists, as this combination is contraindicated.